About Arrakis Therapeutics
Arrakis Therapeutics is a company based in Waltham (United States) founded in 2015 by Raj Parekh. Arrakis Therapeutics has raised $113 million across 2 funding rounds from investors including Pfizer, ARE and WuXi AppTec. The company has 91 employees as of December 31, 2023. Arrakis Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Horizon Discovery, Revolution Medicines, Blueprint Medicines and Syndax, among others.
- Headquarter Waltham, United States
- Employees 91 as on 31 Dec, 2023
- Founders Raj Parekh
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Arrakis Therapeutics, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$113 M (USD)
in 2 rounds
-
Latest Funding Round
$75 M (USD), Series B
Apr 18, 2019
-
Investors
Pfizer
& 12 more
-
Employee Count
91
as on Dec 31, 2023
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Arrakis Therapeutics
Unlock access to complete
Funding Insights of Arrakis Therapeutics
Arrakis Therapeutics has successfully raised a total of $113M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $75 million completed in April 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Arrakis Therapeutics
Arrakis Therapeutics has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Pfizer, ARE and WuXi AppTec.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A life sciences investment firm focused on novel therapeutics is operated.
|
Locked | Locked | Locked | |
|
PE firm investing in the US
|
Locked | Locked | Locked | |
|
Life sciences focused VC firm funding companies in the US and Europe
|
Locked | Locked | Locked |
Investor details for Arrakis Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Arrakis Therapeutics
Investment portfolio details for Arrakis Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Arrakis Therapeutics
Detailed financials for Arrakis Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Arrakis Therapeutics Comparisons
Peer comparison for Arrakis Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Arrakis Therapeutics
Arrakis Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Horizon Discovery, Revolution Medicines, Blueprint Medicines and Syndax, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Genetically modified cell lines are developed using AAV gene-editing platform.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
Detailed competitors of Arrakis Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Arrakis Therapeutics
Complete news archive for Arrakis Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Arrakis Therapeutics
Arrakis Therapeutics was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Arrakis Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Arrakis Therapeutics is a funded company, having raised a total of $113M across 2 funding rounds to date.
As of Dec 31, 2023, the latest employee count at Arrakis Therapeutics is 91.
Arrakis Therapeutics was founded in 2015 in Waltham, United States, within the biotechnology sector. Tools for RNA structure analysis are offered through bioinformatics platforms. These enable identification of RNA targets, design of drug molecules, and selection of therapeutic candidates. Novel drugs are under development for conditions including cancer, central nervous system diseases, and rare genetic disorders, with operations focused on advancing RNA-targeted therapies.
Arrakis Therapeutics's top competitors include Jazz Pharmaceuticals, Horizon Discovery and C4 Therapeutics.
Arrakis Therapeutics has 13 investors. Key investors include Pfizer, ARE, WuXi AppTec, Celgene, and Canaan.